Cardiosphere-Derived Cells Allogeneic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating coronary heart disease and heart failure lack effective and efficient ways to administer stem cells or their derivatives to repair damaged cardiac tissue, often resulting in significant immune responses and delayed treatment availability.
Innovation Solution
A method involving the isolation, culture, and administration of regenerative cells, such as cardiosphere-derived cells, from donor heart tissue, which can be expanded in vitro and administered allogeneically to patients with damaged cardiac tissue, reducing immune response and enabling immediate treatment without the need for autologous harvesting or lengthy preparation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous stem cell harvesting and culturing is performed, then immune response is avoided, but treatment time is significantly delayed
Solution Approach 1:
The patent applies preliminary action by pre-culturing and expanding cardiosphere-derived cells from donor hearts before they are needed for transplantation. This allows the cells to be prepared in advance and stored, eliminating the time delay associated with autologous cell harvesting and culturing while maintaining the therapeutic benefits of stem cell therapy.
Solution Approach 2:
The patent uses donor cardiosphere-derived cells as an intermediary solution between autologous and allogeneic transplantation. These cells serve as a mediator that can be pre-prepared and immunomatched to reduce immune rejection, while avoiding the lengthy preparation time required for autologous cell culturing.
2Loss of time
If allogeneic stem cells are administered, then immediate treatment is possible, but immune response and rejection increase
Solution Approach 1:
The patent applies parameter changes by carefully controlling the immunomatching parameters between donor and recipient. By selecting donors with compatible immunological characteristics, the patent reduces the immune response to allogeneic cells while maintaining the advantage of immediate cell availability.
Solution Approach 2:
The patent uses immunomatching as an intermediary mechanism to bridge the gap between donor and recipient compatibility. This process selects donors whose cells are immunologically compatible with the recipient, reducing rejection while allowing immediate allogeneic transplantation.
3Quantity of substance
If stem cells are cultured extensively in vitro, then cell quantity is increased, but cell potency and differentiation control may be compromised
Solution Approach 1:
The patent applies dynamics by using dynamic culture conditions that can be adjusted during the culturing process. The culture system transitions from conditions that promote cell proliferation to conditions that promote differentiation, allowing the cells to be expanded to the required quantity while maintaining control over their differentiation state.
Solution Approach 2:
The patent uses periodic action by implementing staged culture protocols where different culture conditions are applied at different time periods. The cells are first cultured under conditions that promote expansion, then the culture conditions are changed to promote differentiation, allowing control over both cell quantity and differentiation state.
Data Source
AI summary
The present application relates to methods and compositions for treating diseased or damaged cardiac tissue comprising regenerative cells harvested from donor cardiac tissue. In one embodiment, regenerative cells are harvested from an allogeneic source and after administration result in increased viability and/or functional improvement of damaged or diseased cardiac tissue.